News & Updates

Appendicolith ups appendectomy risk after antibiotic treatment for acute appendicitis

08 Feb 2022 by

The presence of appendicolith is tied to an almost twofold risk of requiring an appendectomy within 30 days in patients who initially received antibiotic therapy for acute uncomplicated appendicitis, according to an analysis of the CODA* study from the US.

Appendicolith ups appendectomy risk after antibiotic treatment for acute appendicitis

08 Feb 2022

Probiotic use in IBD: Yay or nay?

08 Feb 2022 by

Using the probiotic Escherichia coli Nissle 1917 (EcN) as add-on therapy for patients with mild-to-moderate ulcerative colitis (UC) helps induce disease remission and preserve quality of life (QoL) in these patients, according to studies presented at CCC 2022.

Probiotic use in IBD: Yay or nay?

08 Feb 2022

Esmethadone clears phase II trial as adjunctive treatment for major depressive disorder

08 Feb 2022

REL-1017 (esmethadone), a novel N-methyl-D-aspartate receptor channel blocker, demonstrates favourable safety, tolerability, and pharmacokinetic profiles and appears to have rapid and sustained antidepressant effects relative to placebo in major depressive disorder patients with inadequate responses to antidepressant treatments, according to a recent study.

Esmethadone clears phase II trial as adjunctive treatment for major depressive disorder

08 Feb 2022

Apatinib a new treatment alternative for thyroid cancer?

08 Feb 2022 by

In individuals with progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC), the VEGFR-2* inhibitor apatinib demonstrated significant clinical benefits in terms of progression-free survival (PFS) and overall survival (OS), with a manageable safety profile, findings from the phase III REALITY trial suggest.

Apatinib a new treatment alternative for thyroid cancer?

08 Feb 2022

Novel XPO1 inhibitor shows antitumour activity in recurrent glioblastoma

08 Feb 2022

The oral selective inhibitor of exportin-1 (XPO1) selinexor has therapeutic potential in recurrent glioblastoma, yielding favourable responses and clinically relevant 6-month progression-free survival (PFS) rate with manageable side effects requiring dose reductions, according to the results of a phase II trial.

Novel XPO1 inhibitor shows antitumour activity in recurrent glioblastoma

08 Feb 2022

Original New Drug Application Approvals by US FDA (16 - 31 January 2022)

08 Feb 2022

New drug applications approved by US FDA as of 16-31 January 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 January 2022)

08 Feb 2022

Fungal infections common in COVID-19 patients who require mechanical ventilation

07 Feb 2022 by

Patients with COVID-19 who received mechanical ventilation while admitted to the intensive care unit (ICU) have an elevated risk of invasive fungal infections (IFIs), according to results of the MYCOVID study from France. Furthermore, patients with COVID-19–associated pulmonary aspergillosis (CAPA) may be at an increased risk for death.

Fungal infections common in COVID-19 patients who require mechanical ventilation

07 Feb 2022

Adherence to lenalidomide deficient in multiple myeloma patients

07 Feb 2022

Adherence to lenalidomide is remarkably lacking among patients with multiple myeloma at 1 year following treatment initiation, a study has found.

Adherence to lenalidomide deficient in multiple myeloma patients

07 Feb 2022

Combining mogamulizumab with nivolumab of no benefit in advanced solid tumours

07 Feb 2022

The addition of mogamulizumab to nivolumab falls short of improving efficacy of the latter in the treatment of patients with locally advanced or metastatic solid tumours, according to the results of a phase I/II trial.

Combining mogamulizumab with nivolumab of no benefit in advanced solid tumours

07 Feb 2022

Efavirenz efficacy not compromised when switched to lower dose

06 Feb 2022

In the management of virologically suppressed patients living with HIV, efavirenz 400 mg has noninferior efficacy and favourable safety as compared with the 600 mg-based regimen, according to a study from China.

Efavirenz efficacy not compromised when switched to lower dose

06 Feb 2022

News & Updates

Filter by Specialty:

Specialty:

Appendicolith ups appendectomy risk after antibiotic treatment for acute appendicitis

Appendicolith ups appendectomy risk after antibiotic treatment for acute appendicitis

Probiotic use in IBD: Yay or nay?

Probiotic use in IBD: Yay or nay?

Esmethadone clears phase II trial as adjunctive treatment for major depressive disorder

Esmethadone clears phase II trial as adjunctive treatment for major depressive disorder

Apatinib a new treatment alternative for thyroid cancer?

Apatinib a new treatment alternative for thyroid cancer?

Novel XPO1 inhibitor shows antitumour activity in recurrent glioblastoma

Novel XPO1 inhibitor shows antitumour activity in recurrent glioblastoma

Original New Drug Application Approvals by US FDA (16 - 31 January 2022)

Original New Drug Application Approvals by US FDA (16 - 31 January 2022)

Fungal infections common in COVID-19 patients who require mechanical ventilation

Fungal infections common in COVID-19 patients who require mechanical ventilation

Adherence to lenalidomide deficient in multiple myeloma patients

Adherence to lenalidomide deficient in multiple myeloma patients

Combining mogamulizumab with nivolumab of no benefit in advanced solid tumours

Combining mogamulizumab with nivolumab of no benefit in advanced solid tumours

Efavirenz efficacy not compromised when switched to lower dose

Efavirenz efficacy not compromised when switched to lower dose